Delivery Order SPE2DB22D9207-SPE2DB24FH5EU

Award Date 8/27/24
Potential Completion Date 9/18/24
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB program. The $23,211 firm fixed-price contract is for the supply of Xolair 150 mg/mL syringes to support the recurring medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group is a key supplier of pharmaceutical products and medical supplies to the Department of Defense (DoD) and Department of Veterans...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) as a Firm Fixed Price delivery order under the SPE2DB program. The contract, valued at $1,547.40, is for the delivery of Xolair 150 mg/ml syringes to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB program. The $18,612.48 firm fixed-price contract is for the delivery of the pharmaceutical product Xolair 150 mg/mL syringe to support the medical supply needs of Department of Defense (DoD) healthcare facilities. The contract has no set-aside designation and is part of DMS Pharmaceutical Group's broader indefinite delivery contract...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $4,642.20 firm fixed-price delivery order is for the provision of Xolair 150 mg/mL syringes, a specialized pharmaceutical product, with a period of performance through January 25, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA to supply a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $6,963.30 firm fixed-price delivery order is for the pharmaceutical product Xolair 150 mg/mL syringe. This award is part of DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with the DLA to provide a wide range of pharmaceutical items, including both common and specialized medications, to support...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $7,737 firm fixed-price delivery order covers the supply of Xolair 150 mg/mL syringes to support the recurring medical needs of military health facilities. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of Xolair 150 mg/ml syringes. The $9,284.40 firm fixed-price delivery order was issued by the Defense Logistics Agency's (DLA) Medical Supply Chain division, which supports the recurring pharmaceutical needs of Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare facilities nationwide. DMS Pharmaceutical Group holds a significant...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price Delivery Order (SPE2DB23FQ60G) valued at $15,474.00 for the supply of XOLAIR 150 MG/ML syringes. The contract is awarded under the Defense Logistics Agency's (DLA) SPE2DB program, a $499,999,999 indefinite delivery contract (IDC) that runs through December 31, 2025. This IDC allows the DLA to issue delivery orders to DMS Pharmaceutical Group for a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $1,547.40 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the recurring medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) as a firm fixed-price delivery order under the SPE2DB program. The $9,284.40 contract is for the supply of Xolair 150 mg/mL syringes to support the medical needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which enables the agency to issue...
  • SPE2DB22D9207
    Indefinite Delivery Contract
  • SPE2DB22D9207-SPE2DB24FH5EU
    Delivery Order

This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB program. The $15,474 firm fixed-price contract is for the supply of Xolair 150 mg/ml syringes, with a period of performance through September 18, 2024. DMS Pharmaceutical Group is an established supplier of a wide range of pharmaceutical products and medical supplies to the Department of Defense (DoD) and Department of Veterans Affairs (VA) under various prime vendor contracts, including an indefinite delivery contract (IDC) with DLA valued up to $499,999,999. This award does not utilize a set-aside designation and leverages DMS Pharmaceutical Group's status as a woman-owned small business to directly support the recurring medical supply needs of military health facilities worldwide.

Generated 11/26/24, 9:22 AM